Drug Profile

STK 012

Alternative Names: STK-012

Latest Information Update: 14 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Synthekine
Class Antineoplastics; Cytokines; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Non-small cell lung cancer
Phase I Solid tumours

Most Recent Events

07 Nov 2025 Efficacy and adverse event data from a phase Ia/Ib trial in Solid tumours released by Synthekine
30 Oct 2025 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in USA (SC) (NCT05098132)
20 Feb 2025 STK 012 is still in phase I trials for Solid tumours in USA (NCT05098132)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com